-- Lead NNRTI RDEA806 to begin Phase 2b trial in the second quarter of 2008
MONTREAL and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data was presented on the Company's next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds demonstrating potent activity against the human-immunodeficiency virus (HIV), including NNRTI- resistant strains, with the potential for improved performance over current NNRTIs.
The data were presented at the 21st International Conference on Antiviral Research (ICAR) in Montreal, Quebec, Canada.
The compounds in this series are potent against both wild-type and the most common NNRTI-resistant viruses and are more active than efavirenz (Sustiva(R), BMS) and nevirapine (Viramune(R), Boehringer-Ingelheim) against a broad panel of NNRTI-resistant clinical isolates.
"Safer, better tolerated NNRTIs that also work against viruses resistant to the most widely used NNRTIs, are needed to expand the armamentarium," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Our lead NNRTI, RDEA806, has shown the potential to match this profile and we are preparing to progress it into a Phase 2b trial later this quarter. An important part of our business strategy is to progress an additional next generation NNRTI, from the structurally novel series presented today, into Phase 1 later this year."
The poster is available on the Company website (http://www.ardeabio.com) under the title, "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses."
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved